29— DIVISION INFORMATION (SEGMENT REPORTING)

Our activity is organized into three reportable segments corresponding to our three divisions: HIFU, ESWL (including lithotripsy activities) and Distribution. Through these three divisions, we develop, produce, market and distribute non-invasive medical devices, mainly for urological diseases. HIFU division includes sales of Focal One, and related consumables and services, ESWL division includes revenues generated by the existing Sonolith range of lithotripters and, Distribution division includes the sale of complimentary products such as lasers, micro-ultrasound systems and other products from third parties.

The organization of our activities into three divisions better clarified our vision and enhanced our financial reporting of our three businesses HIFU, ESWL and Distribution. This new structure also allows for an improved measurement of our business progress.

The business in which the Company operates is the development, production and distribution of non-invasive medical devices, primarily for the treatment of urological diseases. The divisions s derive their revenues from this activity.

The following tables set forth the key Statement of loss figures, by division for fiscal years 2025 and 2024 and the key balance sheet figures, by division, for fiscal years 2025 and 2024. Division operating profit or loss and division assets are determined in accordance with the same policies as those described in the summary of significant accounting policies and they are reviewed by the CODM, who is the CEO. The CODM uses operating income (loss) as the measure of profit or loss to allocate resources, assess performance, and monitor budgets against actual results.

Interest income and expense, current and deferred income taxes are not allocated to individual divisions. A reconciliation of division operating profit or loss to consolidated net loss is as follows:

Year Ended December 31, 

  ​ ​ ​

2025

  ​ ​ ​

2024

Division operating loss

 

(24,694)

 

(22,225)

Financial (expense) income, net

 

(3,110)

 

606

Foreign Currency exchange (losses) gains, net

 

(1,003)

 

1,348

Income tax (expense) benefit

 

(438)

 

(313)

Consolidated net loss

 

(29,246)

 

(20,584)

A summary of the Company’s operations by division is presented below for years ended December 31, 2025 and 2024:

  ​ ​ ​

HIFU

  ​ ​ ​

ESWL

  ​ ​ ​

DISTRIB

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

2025

Division

Division

Division

Items

consolidated

Sales of goods

 

24,857

 

1,711

 

22,328

 

48,896

Sales of RPPs & leases

 

8,791

 

1,159

 

340

 

10,289

Sales of spare parts and services

 

3,703

 

4,593

 

3,045

 

11,342

Total sales

 

37,351

 

7,463

 

25,712

 

70,527

External other revenues

 

 

 

 

Total revenues

 

37,351

 

7,463

 

25,712

 

70,527

Total COS

 

(19,373)

 

(4,017)

 

(17,135)

 

(40,526)

Gross profit

 

17,978

 

3,446

 

8,577

 

30,001

R&D expenses

 

(8,909)

 

(191)

 

(561)

 

(9,661)

Selling and marketing expenses

 

(20,153)

 

(647)

 

(6,514)

 

(27,315)

G&A expenses

 

(9,594)

 

(509)

 

(2,311)

 

(5,305)

 

(17,720)

Total expenses

 

(38,657)

 

(1,347)

 

(9,386)

 

(5,305)

 

(54,695)

Operating income (loss) from operations

 

(20,679)

 

2,099

 

(809)

 

(5,305)

 

(24,694)

Total Assets

 

36,908

8,935

22,701

10,453

 

78,997

Net cash generated by (used in) investing activities

 

5,165

89

462

 

5,715

Non-current assets

 

13,790

2,250

5,794

 

21,834

Goodwill

 

757

583

1,493

 

2,834

  ​ ​ ​

HIFU

  ​ ​ ​

ESWL

  ​ ​ ​

DISTRIB

  ​ ​ ​

Reconciling

  ​ ​ ​

Total

2024

Division

Division

Division

Items

consolidated

Sales of goods

 

16,046

 

3,768

 

27,850

 

 

47,664

Sales of RPPs & leases

 

6,789

 

1,118

 

329

 

 

8,237

Sales of spare parts and services

 

2,967

 

4,836

 

5,691

 

 

13,495

Total sales

 

25,803

 

9,722

 

33,871

 

 

69,395

External other revenues

 

 

 

 

 

Total revenues

 

25,803

 

9,722

 

33,871

 

 

69,395

Total COS

 

(12,519)

 

(5,949)

 

(22,184)

 

 

(40,652)

Gross profit

 

13,283

 

3,773

 

11,687

 

 

28,744

R&D expenses

 

(7,245)

 

(395)

 

(723)

 

 

(8,363)

Selling and marketing expenses

 

(16,827)

 

(1,412)

 

(9,124)

 

 

(27,363)

G&A expenses

 

(8,109)

 

(656)

 

(2,458)

 

(4,020)

 

(15,243)

Total expenses

 

(32,180)

 

(2,464)

 

(12,305)

 

(4,020)

 

(50,969)

Operating income (loss) from operations

 

(18,897)

 

1,310

 

(618)

 

(4,020)

 

(22,225)

Total Assets

 

31,118

12,074

34,043

12,171

 

89,407

Net cash generated by (used in) investing activities

 

3,351

331

777

 

4,459

Non-current assets

 

10,214

1,524

5,078

 

16,816

Goodwill

 

670

515

1,320

 

2,505

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.